Literature DB >> 29029303

Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine.

Michael N Oxman1,2, Ruth Harbecke1,3, David M Koelle4,5,6,7.   

Abstract

Keywords:  adjuvant; glycoprotein E; influenza vaccine; re-vaccination; zoster vaccine

Mesh：

Substances：

Year:  2017        PMID： 29029303      PMCID： PMC5853975          DOI： 10.1093/infdis/jix484

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  30 in total

1.  THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS.

Authors:  R E HOPE-SIMPSON
Journal:  Proc R Soc Med       Date:  1965-01

2.  Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial.

Authors:  Michael S Simberkoff; Robert D Arbeit; Gary R Johnson; Michael N Oxman; Kathy D Boardman; Heather M Williams; Myron J Levin; Kenneth E Schmader; Lawrence D Gelb; Susan Keay; Kathleen Neuzil; Richard N Greenberg; Marie R Griffin; Larry E Davis; Vicki A Morrison; Paula W Annunziato
Journal:  Ann Intern Med       Date:  2010-05-04       Impact factor: 25.391

Review 3.  Antiviral treatment for preventing postherpetic neuralgia.

Authors:  Ning Chen; Qifu Li; Jie Yang; Muke Zhou; Dong Zhou; Li He
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

4.  Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

Authors:  Hung Fu Tseng; Rafael Harpaz; Yi Luo; Craig M Hales; Lina S Sy; Sara Y Tartof; Stephanie Bialek; Rulin C Hechter; Steven J Jacobsen
Journal:  J Infect Dis       Date:  2016-02-09       Impact factor: 5.226

5.  The Fate of FDA Postapproval Studies.

Authors:  Steven Woloshin; Lisa M Schwartz; Brian White; Thomas J Moore
Journal:  N Engl J Med       Date:  2017-09-21       Impact factor: 91.245

6.  A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.

Authors:  Isabel Leroux-Roels; Geert Leroux-Roels; Frédéric Clement; Pierre Vandepapelière; Ventzislav Vassilev; Edouard Ledent; Thomas C Heineman
Journal:  J Infect Dis       Date:  2012-08-07       Impact factor: 5.226

7.  Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.

Authors:  Syed Sohail Ahmed; Wayne Volkmuth; José Duca; Lorenzo Corti; Michele Pallaoro; Alfredo Pezzicoli; Anette Karle; Fabio Rigat; Rino Rappuoli; Vas Narasimhan; Ilkka Julkunen; Arja Vuorela; Outi Vaarala; Hanna Nohynek; Franco Laghi Pasini; Emanuele Montomoli; Claudia Trombetta; Christopher M Adams; Jonathan Rothbard; Lawrence Steinman
Journal:  Sci Transl Med       Date:  2015-07-01       Impact factor: 17.956

8.  Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.

Authors:  Myron J Levin; Kenneth E Schmader; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

9.  The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults.

Authors:  Kenneth E Schmader; Richard Sloane; Carl Pieper; Paul M Coplan; Alexander Nikas; Patricia Saddier; Ivan S F Chan; Peter Choo; Myron J Levin; Gary Johnson; Heather M Williams; Michael N Oxman
Journal:  Clin J Pain       Date:  2007 Jul-Aug       Impact factor: 3.442

10.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Authors:  Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245
View more
  3 in total

1.  Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).

Authors:  Laura P Hurley; Mandy A Allison; Kathleen L Dooling; Sean T O'Leary; Lori A Crane; Michaela Brtnikova; Brenda L Beaty; Jessica A Allen; Angela Guo; Megan C Lindley; Allison Kempe
Journal:  Vaccine       Date:  2018-10-26       Impact factor: 3.641

2.  High Constitutive Interleukin 10 Level Interferes With the Immune Response to Varicella-Zoster Virus in Elderly Recipients of Live Attenuated Zoster Vaccine.

Authors:  Anne A Gershon; David Brooks; Donald D Stevenson; William K Chin; Michael B A Oldstone; Michael D Gershon
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 3.  COVID-19 Vaccines in Older Adults: Challenges in Vaccine Development and Policy Making.

Authors:  Chih-Kuang Liang; Wei-Ju Lee; Li-Ning Peng; Lin-Chieh Meng; Fei-Yuan Hsiao; Liang-Kung Chen
Journal:  Clin Geriatr Med       Date:  2022-03-21       Impact factor: 3.529
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.